ARNA - アリ―ナ・ファ―マシュ―ティカルズ (Arena Pharmaceuticals Inc.) アリ―ナ・ファ―マシュ―ティカルズ

 ARNAのチャート


 ARNAの企業情報

symbol ARNA
会社名 Arena Pharmaceuticals Inc (アリ―ナ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アリーナ・ファーマシューティカルズ(Arena Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は治療領域にわたって小分子薬物の開発に従事する。同社は、潰瘍性大腸炎の第II相評価におけるエトラサモード(APD334)、クローン病に関連する疼痛の治療のための第II相評価に入るAPD371、及び肺動脈性高血圧(PAH)の第II相評価におけるralinepag(APD811)の3つの主要治験臨床プログラムを有する。同社の医薬品であるLorcaserinは、体重管理の指標として米国と韓国で販売承認を受ける。同社の臨床開発における候補者には、自己免疫疾患のためのAPD334、血管疾患のためのralinepag及び疼痛のためのAPD371が含まれる。同社の協力プログラムには、認知症関連精神病のネロタンセリン、血栓性疾患のテマノグレル、中枢神経系(CNS)適応症の非公開孤児GPCRが含まれる。   アリ―ナ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。医薬品医療ニ―ズに対応するため、Gタンパク質共役型受容体を標的とする薬剤を開発、商品化する。同社が開発した肥満症治療剤「BELVIQ」は、米国食品医薬品局(FDA)に唯一承認された薬剤である。そのほか、肺動脈高血圧症の治療のためのAPD811など、研究開発中の薬剤候補がある。   Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas
本社所在地 6154 Nancy Ridge Drive San Diego CA 92121 USA
代表者氏名 Tina Susan Nova ティナ・スーザン・ノヴァ
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-453-7200
設立年月日 35521
市場名 NASDAQ National Market System
ipoyear 2000年
従業員数 106人
url www.arenapharm.com
nasdaq_url https://www.nasdaq.com/symbol/arna
adr_tso
EBITDA EBITDA(百万ドル) -98.92900
終値(lastsale) 39.7
時価総額(marketcap) 1959123103.3
時価総額 時価総額(百万ドル) 1962.084
売上高 売上高(百万ドル) 13.97000
企業価値(EV) 企業価値(EV)(百万ドル) 1429.45
当期純利益 当期純利益(百万ドル) -112.12500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arena Pharmaceuticals Inc. revenues increased 62% to $5.7M. Net loss before extraordinary items increased 38% to $63M. Revenues reflect Royalty revenue increase from $0K to $1.6M Collaboration and other revenue increase of 17% to $4.2M. Higher net loss reflects Research and development increase of 39% to $44.7M (expense) General and administrative - increase of 41% to $16.6M (expense).

 ARNAのテクニカル分析


 ARNAのニュース

   Cannabis Stock Gainers And Losers From June 25, 2021  2021/06/25 21:24:06 Benzinga
GAINERS: Australis Capital (OTC: AUSAF ) shares closed up 33.89% at $0.27 Arena Pharmaceuticals (NASDAQ: ARNA ) shares closed up 6.75% at $73.34 Invictus MD Strategies (OTC: IVITF ) shares closed up 6.31% at $0.06 Heritage Cannabis Holding (OTC: HERTF ) shares closed up 6.18% at $0.09 Zynerba Pharmaceuticals (NASDAQ: ZYNE ) shares closed up 3.64% at $5.98 RIV Capital (OTC: CNPOF ) shares closed up 3.4% at $1.52 ReneSola (NYSE: SOL ) shares closed up 3.34% at $8.96 Full story available on Benzinga.com
   Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Wire  2021/06/24 07:22:12 Business Wire
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
   At 10.3% Growth Rate Narcolepsy Drugs Market Expected to Reach $5.36 Billion by 2026 | Arena Pharmaceuticals, Jazz Pharmaceuticals Plc.  2021/06/21 14:47:23 OpenPR
UPDATE AVAILABLE ON-DEMAND Narcolepsy is a chronic disabling condition with symptoms such as cataplexy, excessive daytime sleepiness (EDS), sleep paralysis, hypnogogic hallucinations, and disrupted nocturnal sleep. Most of the narcolepsy drugs are used to treat symptoms related to cataplexy and excessive
   Steven Schoch Elected to Arena Pharmaceuticals Board of Directors Wire  2021/06/18 22:20:55 Business Wire
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors Business Wire
   Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)  2021/06/09 00:00:00 BioSpace
Arena Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod.
   Narcolepsy Drugs Market to Reach Valuation of $5.36 Billion by 2026 | Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals  2021/03/10 13:19:05 OpenPR
Increase in prevalence of narcolepsy across the globe, surge in narcolepsy awareness programs, and presence of reimbursement policies regarding narcolepsy are expected to propel the growth of the global narcolepsy drugs market The global narcolepsy drugs market was pegged at $2.43
   Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain  2021/03/03 06:10:00 Benzinga
Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for …
   Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial  2021/03/02 21:05:00 Business Wire
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS). The CAPTIVATE trial randomized a total of 273 participants and was conducted in study s
   Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter  2021/02/23 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “This quarter we were pleased to announce the completion of enrollment of the ELEVATE UC 52 trial for etrasimod and expansion of our cardiovascular franchise to include temanogrel. Our growing and diverse pipeline is supported by a strong cash position,” said Amit D. Munshi, President and CEO of Aren
   The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings  2021/02/20 14:36:28 Benzinga
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week. Bluebird bio Inc (NASDAQ: BLUE ) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. A day after bluebird bio shared the negative tidings, Novartis AG (NYSE: NVS ) announced an agreement with the Bill & Melinda Gates Foundation for funding the development of a single-administration, in-vivo gene therapy to cure sickle cell disease. The week also witnessed the forging of a few alliances and partnerships, a slew of follow-on offerings and some vaccine updates. Here are the key catalytic events for the coming week: Conferences: Annual SVB Leerink Global Healthcare Conference (virtual event): Feb. 22-26 Citi Healthcare Services Virtual Conference (virtual event): Feb. 24-25 Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum (virtual event): Feb. 25-27 PDUFA Dates The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT ) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations.
   Narcolepsy Drugs Market to Reach Valuation of $5.36 Billion by 2026 | Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals  2021/03/10 13:19:05 OpenPR
Increase in prevalence of narcolepsy across the globe, surge in narcolepsy awareness programs, and presence of reimbursement policies regarding narcolepsy are expected to propel the growth of the global narcolepsy drugs market The global narcolepsy drugs market was pegged at $2.43
   Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain  2021/03/03 06:10:00 Benzinga
Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for …
   Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial  2021/03/02 21:05:00 Business Wire
PARK CITY, Utah--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS). The CAPTIVATE trial randomized a total of 273 participants and was conducted in study s
   Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter  2021/02/23 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “This quarter we were pleased to announce the completion of enrollment of the ELEVATE UC 52 trial for etrasimod and expansion of our cardiovascular franchise to include temanogrel. Our growing and diverse pipeline is supported by a strong cash position,” said Amit D. Munshi, President and CEO of Aren
   The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings  2021/02/20 14:36:28 Benzinga
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week. Bluebird bio Inc (NASDAQ: BLUE ) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. A day after bluebird bio shared the negative tidings, Novartis AG (NYSE: NVS ) announced an agreement with the Bill & Melinda Gates Foundation for funding the development of a single-administration, in-vivo gene therapy to cure sickle cell disease. The week also witnessed the forging of a few alliances and partnerships, a slew of follow-on offerings and some vaccine updates. Here are the key catalytic events for the coming week: Conferences: Annual SVB Leerink Global Healthcare Conference (virtual event): Feb. 22-26 Citi Healthcare Services Virtual Conference (virtual event): Feb. 24-25 Americas Committee for Treatment and Research in Multiple Sclerosis, or ACTRIMS, Forum (virtual event): Feb. 25-27 PDUFA Dates The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT ) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アリ―ナ・ファ―マシュ―ティカルズ ARNA Arena Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)